Inhibition of the inflammatory cytokine TNF-α increases adenovirus activity in ovarian cancer via modulation of cIAP1/2 expression

Molecular Therapy

Volumn 19, Issue 3, 2011, Pages 490-499

  Salako, Michael A ^a   Kulbe, Hagen ^a   Ingemarsdotter, Carin K ^a   Pirlo, Katrina J ^a   Williams, Sarah L ^a   Lockley, Michelle ^a   Balkwill, Frances R ^a   McNeish, Iain A ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE; CELL PROTEIN; CELLULAR INHIBITOR OF APOPTOSIS PROTEIN 1; CELLULAR INHIBITOR OF APOPTOSIS PROTEIN 2; INFLIXIMAB; INTERLEUKIN 6; INTERLEUKIN 8; ONCOLYTIC ADENOVIRUS; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; DOWN REGULATION; DRUG EFFICACY; DRUG POTENTIATION; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INHIBITION KINETICS; NONHUMAN; OVARY CANCER; PROTEIN EXPRESSION; RNA INTERFERENCE; TUMOR XENOGRAFT; VIRUS REPLICATION;

ADENOVIRIDAE;

EID: 79952188412     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2010.247     Document Type: Article

References (45)

1. Heise, C, Hermiston, T, Johnson, L, Brooks, G, Sampson-Johannes, A, Williams, A et al. (2000). An adenovirus E1A mutant that demonstrates potent and selective systemic anti-tumoral effcacy. Nat Med 6: 1134-1139.
2. Lockley, M, Fernandez, M, Wang, Y, Li, NF, Conroy, S, Lemoine, N et al. (2006). Activity of the adenoviral E1A deletion mutant dl922-947 in ovarian cancer: comparison with E1A wild-type viruses, bioluminescence monitoring, and intraperitoneal delivery in icodextrin. Cancer Res 66: 989-998. (Pubitemid 43165967)
3. Baird, SK, Aerts, JL, Eddaoudi, A, Lockley, M, Lemoine, NR and McNeish, IA (2008). Oncolytic adenoviral mutants induce a novel mode of programmed cell death in ovarian cancer. Oncogene 27: 3081-3090. (Pubitemid 351693172)
4. Curiel, DT, Preuss, M, Wang, M, Kimball, KJ, Barnes, MN, Wan, W et al. (2010). A phase I study of the infectivity enhanced CRAd Ad5-Δ24RGD for recurrent gynecologic cancer. J Clin Oncol 28 [Abstr 5107].
5. Reid, T, Galanis, E, Abbruzzese, J, Sze, D, Wein, LM, Andrews, J et al. (2002). Hepatic arterial infusion of a replication-selective oncolytic adenovirus (dl1520): phase II viral, immunologic, and clinical endpoints. Cancer Res 62: 6070-6079. (Pubitemid 35244455)
6. Raper, SE, Chirmule, N, Lee, FS, Wivel, NA, Bagg, A, Gao, GP et al. (2003). Fatal systemic infammatory response syndrome in a ornithine transcarbamylase defcient patient following adenoviral gene transfer. Mol Genet Metab 80: 148-158. (Pubitemid 37272241)
7. Liu, Q, Zaiss, AK, Colarusso, P, Patel, K, Haljan, G, Wickham, TJ et al. (2003). The role of capsid-endothelial interactions in the innate immune response to adenovirus vectors. Hum Gene Ther 14: 627-643. (Pubitemid 36543435)
8. Di Paolo, NC, Miao, EA, Iwakura, Y, Murali-Krishna, K, Aderem, A, Flavell, RA et al. (2009). Virus binding to a plasma membrane receptor triggers interleukin-1 α-mediated proinfammatory macrophage response in vivo. Immunity 31: 110-121.
9. Muruve, DA, Pétrilli, V, Zaiss, AK, White, LR, Clark, SA, Ross, PJ et al. (2008). The infammasome recognizes cytosolic microbial and host DNA and triggers an innate immune response. Nature 452: 103-107. (Pubitemid 351355095)
10. Bowen, G P, Borgland, SL, Lam, M, Libermann, TA, Wong, NC and Muruve, DA (2002). Adenovirus vector-induced infammation: capsid-dependent induction of the C-C chemokine RANTES requires NF-κB. Hum Gene Ther 13: 367-379. (Pubitemid 34251502)
11. Tibbles, LA, Spurrell, JC, Bowen, GP, Liu, Q, Lam, M, Zaiss, AK et al. (2002). Activation of p38 and ERK signaling during adenovirus vector cell entry lead to expression of the C-X-C chemokine IP-10. J Virol 76: 1559-1568. (Pubitemid 34094602)
12. Palmer, DH, Chen, MJ, Searle, PF, Kerr, DJ and Young, LS (2005). Inhibition of NF-κB enhances the cytotoxicity of virus-directed enzyme prodrug therapy and oncolytic adenovirus cancer gene therapy. Gene Ther 12: 1187-1197. (Pubitemid 41136313)
13. Kirn, D (2000). Replication-selective oncolytic adenoviruses: virotherapy aimed at genetic targets in cancer. Oncogene 19: 6660-6669. (Pubitemid 32197705)
14. Locksley, RM, Killeen, N and Lenardo, MJ (2001). The TNF and TNF receptor superfamilies: integrating mammalian biology. Cell 104: 487-501. (Pubitemid 32201945)
15. Micheau, O and Tschopp, J (2003). Induction of TNF receptor I-mediated apoptosis via two sequential signaling complexes. Cell 114: 181-190. (Pubitemid 36936912)
16. Balkwill, F (2009). Tumour necrosis factor and cancer. Nat Rev Cancer 9: 361-371.
17. Moore, RJ, Owens, DM, Stamp, G, Arnott, C, Burke, F, East, N et al. (1999). Mice defcient in tumor necrosis factor-α are resistant to skin carcinogenesis. Nat Med 5: 828-831. (Pubitemid 29318619)
18. Arnott, CH, Scott, KA, Moore, RJ, Hewer, A, Phillips, DH, Parker, P et al. (2002). Tumour necrosis factor-α mediates tumour promotion via a PKC α- and AP-1-dependent pathway. Oncogene 21: 4728-4738. (Pubitemid 34879448)
19. Naylor, MS, Stamp, GW, Foulkes, WD, Eccles, D and Balkwill, FR (1993). Tumor necrosis factor and its receptors in human ovarian cancer. Potential role in disease progression. J Clin Invest 91: 2194-2206. (Pubitemid 23141496)
20. Kulbe, H, Thompson, R, Wilson, JL, Robinson, S, Hagemann, T, Fatah, R et al. (2007). The infammatory cytokine tumor necrosis factor-α generates an autocrine tumor-promoting network in epithelial ovarian cancer cells. Cancer Res 67: 585-592. (Pubitemid 46192196)
21. Madhusudan, S, Muthuramalingam, SR, Braybrooke, JP, Wilner, S, Kaur, K, Han, C et al. (2005). Study of etanercept, a tumor necrosis factor-α inhibitor, in recurrent ovarian cancer. J Clin Oncol 23: 5950-5959.
22. Brown, ER, Charles, KA, Hoare, SA, Rye, RL, Jodrell, DI, Aird, RE et al. (2008). A clinical study assessing the tolerability and biological effects of infiximab, a TNF-α inhibitor, in patients with advanced cancer. Ann Oncol 19: 1340-1346. (Pubitemid 351911969)
23. Yu, D, Wolf, JK, Scanlon, M, Price, JE and Hung, MC (1993). Enhanced c-erbB-2/neu expression in human ovarian cancer cells correlates with more severe malignancy that can be suppressed by E1A. Cancer Res 53: 891-898. (Pubitemid 23077880)
24. Leyton, J, Lockley, M, Aerts, JL, Baird, SK, Aboagye, EO, Lemoine, NR et al. (2006). Quantifying the activity of adenoviral E1A CR2 deletion mutants using renilla luciferase bioluminescence and 3'-deoxy-3'-[18F]fuorothymidine positron emission tomography imaging. Cancer Res 66: 9178-9185. (Pubitemid 44521138)
25. Ingemarsdotter, CK, Baird, SK, Connell, CM, Oberg, D, Hallden, G, and McNeish, IA (2010). Low-dose paclitaxel synergizes with oncolytic adenoviruses via mitotic slippage and apoptosis in ovarian cancer. Oncogene (epub ahead of print
26. Varfolomeev, E, Goncharov, T, Fedorova, AV, Dynek, JN, Zobel, K, Deshayes, K et al. (2008). c-IAP1 and c-IAP2 are critical mediators of tumor necrosis factor α (TNFα)-induced NF-κB activation. J Biol Chem 283: 24295-24299.
27. Varfolomeev, E, Blankenship, JW, Wayson, SM, Fedorova, AV, Kayagaki, N, Garg, P et al. (2007). IAP antagonists induce autoubiquitination of c-IAPs, NF-κB activation, and TNFα-dependent apoptosis. Cell 131: 669-681. (Pubitemid 350087204)
28. Vince, JE, Wong, WW, Khan, N, Feltham, R, Chau, D, Ahmed, AU et al. (2007). IAP antagonists target cIAP1 to induce TNFα-dependent apoptosis. Cell 131: 682-693. (Pubitemid 350103599)
29. Vince, JE, Chau, D, Callus, B, Wong, WW, Hawkins, CJ, Schneider, P et al. (2008). TWEAK-FN14 signaling induces lysosomal degradation of a cIAP1-TRAF2 complex to sensitize tumor cells to TNFα. J Cell Biol 182: 171-184. (Pubitemid 352008630)
30. Conze, DB, Albert, L, Ferrick, DA, Goeddel, DV, Yeh, WC, Mak, T et al. (2005). Posttranscriptional downregulation of c-IAP2 by the ubiquitin protein ligase c-IAP1 in vivo. Mol Cell Biol 25: 3348-3356. (Pubitemid 40464334)
31. Tamanini, A, Nicolis, E, Bonizzato, A, Bezzerri, V, Melotti, P, Assael, BM et al. (2006). Interaction of adenovirus type 5 fber with the coxsackievirus and adenovirus receptor activates infammatory response in human respiratory cells. J Virol 80: 11241-11254. (Pubitemid 44706564)
32. Nishimoto, N, Terao, K, Mima, T, Nakahara, H, Takagi, N and Kakehi, T (2008). Mechanisms and pathologic signifcances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease. Blood 112: 3959-3964.
33. Shayakhmetov, DM, Li, ZY, Ni, S and Lieber, A (2004). Analysis of adenovirus sequestration in the liver, transduction of hepatic cells, and innate toxicity after injection of fber-modifed vectors. J Virol 78: 5368-5381. (Pubitemid 38581487)
34. Shayakhmetov, DM, Gaggar, A, Ni, S, Li, ZY and Lieber, A (2005). Adenovirus binding to blood factors results in liver cell infection and hepatotoxicity. J Virol 79: 7478-7491. (Pubitemid 40756784)
35. Engler, H, Machemer, T, Philopena, J, Wen, SF, Quijano, E, Ramachandra, M et al. (2004). Acute hepatotoxicity of oncolytic adenoviruses in mouse models is associated with expression of wild-type E1a and induction of TNF-α. Virology 328: 52-61. (Pubitemid 39221912)
36. Scott, FL, Denault, JB, Riedl, SJ, Shin, H, Renatus, M and Salvesen, GS (2005). XIAP inhibits caspase-3 and -7 using two binding sites: evolutionarily conserved mechanism of IAPs. EMBO J 24: 645-655. (Pubitemid 40343265)
37. Srinivasula, SM, Hegde, R, Saleh, A, Datta, P, Shiozaki, E, Chai, J et al. (2001). A conserved XIAP-interaction motif in caspase-9 and Smac/DIABLO regulates caspase activity and apoptosis. Nature 410: 112-116. (Pubitemid 32225846)
38. Deveraux, QL, Roy, N, Stennicke, HR, Van Arsdale, T, Zhou, Q, Srinivasula, SM et al. (1998). IAPs block apoptotic events induced by caspase-8 and cytochrome c by direct inhibition of distinct caspases. EMBO J 17: 2215-2223. (Pubitemid 28171907)
39. Tenev, T, Zachariou, A, Wilson, R, Ditzel, M and Meier, P (2005). IAPs are functionally non-equivalent and regulate effector caspases through distinct mechanisms. Nat Cell Biol 7: 70-77. (Pubitemid 40123385)
40. Bertrand, MJ, Milutinovic, S, Dickson, KM, Ho, WC, Boudreault, A, Durkin, J et al. (2008). cIAP1 and cIAP2 facilitate cancer cell survival by functioning as E3 ligases that promote RIP1 ubiquitination. Mol Cell 30: 689-700. (Pubitemid 351818251)
41. Choi, YE, Butterworth, M, Malladi, S, Duckett, CS, Cohen, GM and Bratton, SB (2009). The E3 ubiquitin ligase cIAP1 binds and ubiquitinates caspase-3 and -7 via unique mechanisms at distinct steps in their processing. J Biol Chem 284: 12772-12782.
42. Prestwich, RJ, Ilett, EJ, Errington, F, Diaz, RM, Steele, L P, Kottke, T et al. (2009). Immune-mediated antitumor activity of reovirus is required for therapy and is independent of direct viral oncolysis and replication. Clin Cancer Res 15: 4374-4381.
43. Harrison, ML, Obermueller, E, Maisey, NR, Hoare, S, Edmonds, K, Li, NF et al. (2007). Tumor necrosis factor α as a new target for renal cell carcinoma: two sequential phase II trials of infiximab at standard and high dose. J Clin Oncol 25: 4542-4549. (Pubitemid 350035310)
44. McNeish, IA, Tenev, T, Bell, S, Marani, M, Vassaux, G and Lemoine, N (2001). Herpes simplex virus thymidine kinase/ganciclovir-induced cell death is enhanced by co-expression of caspase-3 in ovarian carcinoma cells. Cancer Gene Ther 8: 308-319. (Pubitemid 32480068)
45. Mosmann, T (1983). Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65: 55-63. (Pubitemid 14203433)